Can-Fite receives notice of allowance for US patent for psoriasis treatment

Can-Fite BioPharma announced it has received a notice of allowance from the U.S. Patent and Trademark Office for CF101 as a psoriasis treatment.

The patent is expected to be issued in the next few weeks and covers CF101, an A3 adenosine receptor agonist, to be used as oral daily treatment for patients with moderate-to-severe plaque psoriasis, according to a press release.

CF101, an orally bioavailable drug, is currently developed for treating autoimmune diseases including rheumatoid arthritis and psoriasis, the release stated.

The notice comes at the close of a phase 2/3, double-blind, placebo-controlled study at 17 clinical centers in the U.S., Europe and Israel that tested the efficacy of CF101 as treatment for 326 patients with moderate-to-severe plaque psoriasis. Interim results from the trial were positive, as were final results from a prior phase 2 trial for CF101 in psoriasis, according to Can-Fite.

“This notice of allowance comes at a key time for us, as we … plan to announce top-line results [of the phase 2/3 study] by the end of March,” Pnina Fishman, PhD, CEO of Can-Fite, said in the press release. “Should these results be favorable, then we believe this patent covering CF101 for psoriasis will significantly increase the value of our patent portfolio.”

Reference: www.canfite.com.